|
| Press Releases |
|
 |
|
| Wednesday, July 31, 2024 |
|
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
| Monday, July 29, 2024 |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Tuesday, July 16, 2024 |
|
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社（本社：東京都、以下 佐藤製薬）と締結したことをお知らせします。 more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「LEQEMBI」（レカネマブ）が香港においてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性 アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（香港製品名：「樂意保(R)」、一般名：レカネマブ）について、香港衛生署（Department of Health）より新薬承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Mooreast Holdings Announces Business Update
Apr 25, 2025 10:00 HKT/SGT
|
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
Apr 24, 2025 22:42 HKT/SGT
|
|
|
TransNusa Increases Scheduled Flight Frequency to Singapore
Apr 24, 2025 22:09 HKT/SGT
|
|
|
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
Apr 24, 2025 20:49 HKT/SGT
|
|
|
君圣泰医药三项创新研究成果即将亮相2025欧肝会(EASL)
Apr 24, 2025 18:35 HKT/SGT
|
|
|
MyJCB App Wins "iF DESIGN AWARD 2025"
Apr 24, 2025 17:00 JST
|
|
|
Honda、2025年3月度 四輪車 生産・販売・輸出実績を発表
Apr 24, 2025 15:15: JST
|
|
|
トヨタ、米国ウェストバージニア工場に8,800万ドルを追加投資
Apr 24, 2025 14:30: JST
|
|
|
MHIEC Completes Renovation of Core Facilities for Arita Municipal Recycle Plaza in Saga Prefecture
Apr 24, 2025 15:01 JST
|
|
|
トヨタ、2024年度 販売・生産・輸出実績を発表
Apr 24, 2025 13:35: JST
|
|
|
Earth Day Special: foundit Report Reveals 27% Surge in Green Jobs as Singapore Accelerates Sustainability Push
Apr 24, 2025 13:00 HKT/SGT
|
|
|
AI產業延續高景氣 明略科技講出企業級「DeepSeek+Manus」好故事
Apr 24, 2025 10:50 HKT/SGT
|
|
|
AI产业延续高景气 明略科技讲出企业级「DeepSeek+Manus」好故事
Apr 24, 2025 10:44 HKT/SGT
|
|
|
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
Apr 24, 2025 10:23 JST
|
|
|
MHI Thermal Systems Wins German Red Dot Design Award 2025
Apr 24, 2025 10:11 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
